Clinical pharmacology of phenelzine.
There is renewed interest in the clinical pharmacology of phenelzine sulfate and other monoamine oxidase (MAO) inhibitors. Newer clinical and analytic techniques recently have been applied to investigations of this class of drugs in man. The results show that drugs such as phenelzine are effective in nonendogenous depression and phobic disorders. Clinical response to phenelzine is related to platelet MAO inhibition and dosage per unit body weight. High percent MAO inhibition in platelets at two weeks is associated with greater improvement after a six-week course of treatment. Our data show that a safe, effective phenelzine dose in 1 mg/kg body weight per day. These results have delineated the pharmacologic and therapeutic effects of phenelzine and support a continuing role for MAO inhibitors in psychopharmacology.
D000107:Acetylation; D000123:Acetyltransferases / Q000235:genetics; D000275:Adjustment Disorders / Q000188:drug therapy / Q000201:enzymology; D000639:Amitriptyline / Q000627:therapeutic use; D001792:Blood Platelets / Q000201:enzymology; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy / Q000201:enzymology*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D008995:Monoamine Oxidase / Q000097:blood; D010624:Phenelzine / Q000627:therapeutic use*; D010641:Phenotype; D010698:Phobic Disorders / Q000188:drug therapy / Q000201:enzymology; D011569:Psychiatric Status Rating Scales
D000639:Amitriptyline; D008995:Monoamine Oxidase; D000123:Acetyltransferases; D010624:Phenelzine